The Quotient media kit is designed to help journalists research our company for background information or follow-up stories. Please contact us if you need more detailed information or to schedule interviews.

Approved imagery

Browse through our approved corporate photos. These images may be used for editorial purposes as long as the connection to Quotient is clearly recognizable. Commercial use is prohibited.

Image Caption Size Download
1 Hand, close-up of microarray 2.1 MB JPG
2 MosaiQ by Quotient instrument and lab technician 2.5 MB JPG
3 MosaiQ by Quotient instrument and microarray cartridge loading dock 2.3 MB JPG
4 Lab technicians blood sample, lab 2.5 MB JPG
5 MosaiQ COVID-19 Antibody Microarray 6.0 MB MP4
6 MosaiQ COVID-19 Antibody Microarray Infographic 0.2 MB PDF


Approved company descriptions


Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. Quotient has two key product portfolios, Alba by Quotient, quality blood bank reagents used in laboratories around the world, and MosaiQ™ by Quotient, the world’s first fully automated, consolidated testing platform. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. MosaiQ by Quotient has been recognized with a Red Dot Product Design Award.


Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multimodal, multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. A serological test was developed in April 2020 in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and is the subject of an Emergency Use Authorization issued by the U.S. Food and Drug Administration.  The COVID-19 antibody test is available for distribution in the U.S., the EU, the UK and Switzerland. In April 2021, the full MosaiQ by Quotient system has been recognized with a Red Dot Product Design Award. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

Meet our management team

We have over 30 years’ experience manufacturing and supplying conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market. We are developing MosaiQ by Quotient, our proprietary technology platform, to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology, significantly reducing the cost of blood grouping in the donor and patient testing environments, while improving patient outcomes.

Manuel O. Méndez, Chief Executive Officer

Manuel O. Méndez

Manuel O. Méndez joined Quotient (NASDAQ:QTNT)  as the company’s Chief Executive Officer in April 2021. 

He brings over 30 years of experience in the diagnostics and life science markets. Mr. Méndez joins Quotient from Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services where he served as the Senior Vice President and Chief Commercial Officer. He played a key role in accelerating growth and supporting the COVID-19 efforts.  Before joining Quest, he was living in Germany and served as SVP and Head of Global Commercial Operations and a member of QIAGEN N.V. Executive Committee, a worldwide provider of Sample to Insight solutions for molecular testing. Manuel has held a variety of senior leadership roles with Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies, and bioMerieux – living in the United States, Europe, Asia, and Latin America.

An American citizen, Mr. Méndez received an MBA from Northwestern University's Kellogg School of Management and a bachelor's degree in biomedical engineering from Boston University. 

Peter Buhler, Chief Financial Officer

Peter Buhler

Peter Buhler joined Quotient (NASDAQ:QTNT) as the company’s Chief Financial Officer in February 2020. Mr Buhler has more than 20 years of experience in the strategic and financial leadership of life science and technology businesses in both the public and private sectors, more recently with Zaluvida AG, where he served as Group Chief Financial Officer.

In addition, Mr Buhler served as Group Chief Financial Officer of Greer Plc, a global leader in allergy immunotherapy headquartered in London.

While there, Mr Buhler led a complex merger project to combine a French and a US Group through the creation of a UK holding. Previously, he served as Head of Finance, Commercial Europe at Merck Serono SA and Finance Director EMEA at Logitech SA.

He is a Swiss Certified Accountant and an Executive MBA from the Swiss Business School in Zurich.

Christian Albrich, Chief People Officer

Christian Albrich

Christian Albrich joined Quotient (NASDAQ:QTNT) as the company’s Chief People Officer in September 2021.

He brings 30 years of HR experience in the healthcare industry, designing effective and business-aligned people strategies, fostering high-performing cultures, and leading organizational development initiatives. Previously, he spent 20 years with Actelion Pharmaceuticals, now a JANSSEN Pharmaceutical company of Johnson & Johnson, where he served as the Senior Vice President and Head of Global Human Resources. Joining Actelion at the start-up phase, he transformed the HR function to support the rapid growth of the company. Prior to joining Actelion, Christian was Human Resources Director at Serono Pharmaceuticals in France and Belgium.

Dr. Ginocchio, Chief Scientific & Medical Officer

Dr. Ginocchio

Dr. Ginocchio joined Quotient (NASDAQ:QTNT) as the Company’s Chief Scientific & Medical Officer in October 2021.

She brings 40 years of experience clinical diagnostics, laboratory management, and medical education. Dr. Ginocchio joins the Company from bioMérieux/BioFire where she held the role of Senior Vice President, Global Medical Affairs. In this capacity she directed the BioFire post-market study program, BioFire medical education and training, and provided key medical insight for new product development. Prior to joining bioMérieux/BioFire, Dr Ginocchio directed over 150 laboratory professionals in a core facility that provided state-of-the-art diagnostic testing and research opportunities for 11 hospitals, including 3 Academic Centers. She was responsible for all areas of Infectious Disease diagnostics, including Microbiology, Virology, Molecular Diagnostics, Immunology/Serology, Hepatitis and HIV testing services. With over 115 peer reviewed publications, Dr. Ginocchio has been a speaker at more than 250 national and international conferences and is considered an international expert in molecular diagnostics and clinical virology. She attained the rank of Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell Health, NY. Dr Ginocchio remains active in numerous professional societies, and she is a voting member of the President’s Advisory Council for Combating Antibiotic Resistant Bacteria (PACCARB). 

Dr. Michael Hausmann, Chief Technology Officer

Dr. Michael Hausmann

Dr. Michael Hausmann joined Quotient (NASDAQ:QTNT) as the company’s Chief Technology Officer in August 2021. 

He has 24 years of experience in the in vitro diagnostics industry, including extensive R&D leadership experience at companies such as: Abbott, bioMérieux and most recently, Thermo Fisher Scientific.

He developed the ex-US Architect Infectious Disease portfolio for blood screening and diagnostics at Abbott; at bioMérieux, led the team to develop the VIDAS & VIDAS 3 assays. Most recently, at Thermo Fisher Scientific, he expanded the adoption of BRAHMS Procalcitonin in China and the US.

Dr. Hausmann holds a Ph.D. in Biology from the Max-Planck-Institute of Immunobiology and a MSc degree in Chemistry from Albert-Ludwigs-University in Freiburg, Germany. 

Mohammad El Khoury, Chief Commercial Officer

Mohammad El Khoury

Mohammad El Khoury joined Quotient (NASDAQ:QTNT) as the company’s Chief Commercial Officer in October 2021.

He brings 30 years of experience in driving commercial strategies for major diagnostic portfolios some of which included, infectious disease, transfusion, digital PCR, and COVID-19 testing solutions. Mr. El Khoury joins the Company from QIAGEN (NYSE:QGEN), where he served as President, Head of Global Sales of Molecular Diagnostics leading a global team of over 600 people. He led the expansion strategies across different geographies. Prior to that, he served as Vice President, Commercial Performance at bioMérieux, leading a cross-functional international team. While there, he secured top-line profitability worldwide by driving regional go-to-market strategies and execution plans. Mr. El Khoury also brings international experience in leadership roles at Roche Diagnostics and GE Healthcare.

Office locations

Global (HQ)

Quotient Suisse SA

B1, Business Park Terre Bonne
Route de Crassier 13
Eysins, 1262



5 James Hamilton Way
Milton Bridge
Penicuik EH26 0BF
United Kingdom



301 S State St
Newtown, PA 18940-1997
United States


We are proud to be active and responsive on Twitter and LinkedIn.
Follow us to stay updated on Quotient news, announcements & updates.